Revenue from Contract with Customer [Text Block]

Revenue

Disaggregation of revenue

In the following tables, revenue is disaggregated by primary geographical markets and major goods and service lines.


	Reportable Segments
	Three Months Ended
	September 29, 2024						October 1, 2023
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	163,071	$	139,254	$	302,325	$	159,916	$	133,679	$	293,595
Europe	67,708		114,330		182,038		72,638		105,420		178,058
Asia	70,142		129,544		199,686		75,301		123,785		199,086
	$	300,921	$	383,128	$	684,049	$	307,855	$	362,884	$	670,739

Major goods/service lines
Life Sciences reagents	$	178,779	$	—	$	178,779	$	171,924	$	—	$	171,924
Life Sciences instruments	78,797		—		78,797		89,658		—		89,658
Life Sciences software	43,345		—		43,345		46,273		—		46,273
Reproductive health	—		132,743		132,743		—		123,169		123,169
Applied genomics	—		52,691		52,691		—		53,434		53,434
Immunodiagnostics	—		197,694		197,694		—		186,281		186,281
	$	300,921	$	383,128	$	684,049	$	307,855	$	362,884	$	670,739


	Reportable Segments
	Nine Months Ended
	September 29, 2024						October 1, 2023
	Life Sciences		Diagnostics		Total		Life Sciences		Diagnostics		Total
	(In thousands)
Primary geographical markets
Americas	$	487,812	$	416,650	$	904,462	$	508,565	$	405,885	$	914,450
Europe	204,711		340,477		545,188		227,630		326,942		554,572
Asia	225,282		350,722		576,004		236,454		349,194		585,648
	$	917,805	$	1,107,849	$	2,025,654	$	972,649	$	1,082,021	$	2,054,670

Major goods/service lines
Life Sciences reagents	$	532,856	$	—	$	532,856	$	554,010	$	—	$	554,010
Life Sciences instruments	245,959		—		245,959		285,933		—		285,933
Life Sciences software	138,990		—		138,990		132,706		—		132,706
Reproductive health	—		385,793		385,793		—		373,911		373,911
Applied genomics	—		151,425		151,425		—		175,941		175,941
Immunodiagnostics	—		570,631		570,631		—		532,169		532,169
	$	917,805	$	1,107,849	$	2,025,654	$	972,649	$	1,082,021	$	2,054,670

Contract Balances

Contract assets: The unbilled receivables (contract assets) primarily relate to the Company’s right to consideration for work completed but not billed at the reporting date. The unbilled receivables are transferred to trade receivables when billed to customers. Contract assets are generally classified as current assets and are included in “Accounts receivable, net” in the condensed consolidated balance sheets.

Contract liabilities: The contract liabilities primarily relate to the advance consideration received from customers for products and related services for which transfer of control has not occurred at the balance sheet date. Contract liabilities are classified as either current in “Accounts payable” or “Accrued expenses and other current liabilities” or as long-term in “Deferred taxes and long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. The contract liability balances at the beginning of each period presented were generally fully recognized in the subsequent three month period. The performance obligations that are unsatisfied (or partially unsatisfied) at the end of each period presented are not material to the Company.

Contract balances were as follows: